Braidwell LP Cuts Position in TransMedics Group, Inc. $TMDX

Braidwell LP trimmed its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 7.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 854,884 shares of the company’s stock after selling 67,216 shares during the period. TransMedics Group comprises about 2.0% of Braidwell LP’s portfolio, making the stock its 20th biggest position. Braidwell LP owned 2.53% of TransMedics Group worth $57,517,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. OneDigital Investment Advisors LLC increased its stake in shares of TransMedics Group by 52.6% during the first quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company’s stock worth $403,000 after buying an additional 2,065 shares during the period. Principal Financial Group Inc. increased its stake in shares of TransMedics Group by 2.8% during the first quarter. Principal Financial Group Inc. now owns 198,427 shares of the company’s stock worth $13,350,000 after buying an additional 5,480 shares during the period. Vontobel Holding Ltd. purchased a new stake in shares of TransMedics Group during the first quarter worth approximately $291,000. New York State Teachers Retirement System increased its stake in shares of TransMedics Group by 183.2% during the first quarter. New York State Teachers Retirement System now owns 21,949 shares of the company’s stock worth $1,477,000 after buying an additional 14,200 shares during the period. Finally, Sugar Maple Asset Management LLC purchased a new stake in shares of TransMedics Group during the first quarter worth approximately $740,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Stock Performance

Shares of TMDX opened at $114.96 on Monday. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The firm has a market cap of $3.92 billion, a PE ratio of 59.57 and a beta of 2.18. The company’s 50 day simple moving average is $120.24 and its 200-day simple moving average is $103.29. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $172.78.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.44. The business had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same period last year, the firm posted $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on TMDX shares. Morgan Stanley increased their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Piper Sandler reiterated an “overweight” rating and issued a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Wall Street Zen lowered shares of TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday. Canaccord Genuity Group increased their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the company a “buy” rating in a research note on Tuesday, July 15th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Monday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $123.00.

Insider Activity

In other news, insider Anil P. Ranganath sold 686 shares of the firm’s stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider directly owned 13,955 shares in the company, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 7.00% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.